NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

December 31, 2013

Conditions

Type 2 Diabetes MellitusAlbuminuria

Interventions

DRUG

NOX-E36

0.5 mg/kg study drug or placebo as SC injections twice a week

Trial Locations (24)

Prague

Aschaffenburg

Dortmund

Düsseldorf

Hanover

Kronberg

Mainz

Mannheim

Offenbach

Schwabenheim

Witten

Balatonfüred

Budapest

Gyula

Miskolc

Pécs

Szeged

Bialystok

Grodzisk Mazowiecki

Katowice

Warsaw

Arad

Bucharest

Timișoara

All Listed Sponsors

lead

TME Pharma AG

INDUSTRY

NCT01547897 - NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria | Biotech Hunter | Biotech Hunter